The prospects of DNA damage repair variants guiding platinum compounds in the treatment of triple negative breast cancer.
10.3760/cma.j.cn112152-20210427-00351
- Author:
Xue WANG
1
;
Jian YUE
1
;
Yi Kun KANG
1
;
Song Lin GAO
1
;
Peng YUAN
1
Author Information
1. Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
DNA damage repair;
Platinum;
Triple negative breast cancer
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
DNA Damage;
DNA Repair;
Humans;
Pharmaceutical Preparations;
Platinum/therapeutic use*;
Platinum Compounds/therapeutic use*;
Triple Negative Breast Neoplasms/genetics*
- From:
Chinese Journal of Oncology
2022;44(1):68-72
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer (TNBC) is prone to recurrence and metastasis, which is the subtype of poorest prognosis. Chemotherapy is the main treatment, although there is lack of effective adjuvant chemotherapy regimens. The unsatisfactory efficacy of chemotherapy has been a bottleneck in improving the outcome of TNBC. Platinum compounds act directly on DNA to kill tumor cells, and they have a stronger killing effect on tumor cells carrying DNA damage repair (DDR) defects, which is an important entry point to improve the efficacy of TNBC. Biomarkers for predicting the efficacy of platinum drugs in TNBC treatment have always been a hot topic. The DDR pathway contains a large number of related genes, and recent studies have shown that deficiencies in the DDR pathway may be associated with the efficacy of platinum drugs, which is expected to be a biomarker for predicting the efficacy of platinum drugs in breast cancer treatment.
